Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

- Ackland, Stephen P., Gebski, V., Forbes, J. F., Coates, A. S., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., Van Hazel, G., Levi, J., Simes, R. J.

Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II

- Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., Cuzick, J.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

- Dowsett, M., Forbes, J. F., Dubsky, P., Gnant, M., Kaufmann, M., Kilburn, L., Perrone, F., Rea, D., Thuerlimann, B., van de Velde, C., Pan, H., Peto, R., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., Coombes, R. C., Cuzick, J.

Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial

- Juraskova, I., Butow, P., Bonner, C., Bell, M. L., Smith, A. B., Seccombe, M., Boyle, F., Reaby, L., Cuzick, J., Forbes, J. F.

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

- McCarthy, N., Boyle, F., Gebski, V., Veillard, A. S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., Forbes, J. F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P. A., Chirgwin, J., Abdi, E.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an international breast cancer study group report

- Karlsson, P., Cole, B. F., Forbes, J. F., Gelber, R. D., Goldhirsch, A., Gruber, G., Chua, B. H., Price, K. N., Lindtner, J., Collins, J. P., Kovacs, A., Thurlimann, B., Crivellari, D., Castiglione-Gertsch, M.

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

- Sestak, I., Kealy, R., Nikoloff, M., Fontecha, M., Forbes, J. F., Howell, A., Cuzick, J.

The sequential use of endocrine treatment for advanced breast cancer: where are we?

- Barrios, C., Forbes, J. F., Hudis, C., Robertson, J. F. R., Jonat, W., Conte, P., Gradishar, W., Buzdar, A., Gelmon, K., Gnant, M., Bonneterre, J., Toi, M.

Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

- Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS Trial

- Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H., Fentiman, I. S., George, W. D.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

- Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., Australian New Zealand Breast Cancer Trials Group

Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS)

- Juraskova, I., Butow, P., Lopez, A., Seccombe, M., Coates, A., Boyle, F., McCarthy, N., Reaby, L., Forbes, J. F.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

- Bernhard, J., Zahrieh, D., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Coates, A. S., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., Forbes, J. F., Aebi, S., Yeo, W., Thurlimann, B.